Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
BACKGROUND
Over the past decade, high dose chemotherapy with autologous bone marrow (HDC-ABMT) support has been used increasingly in the treatment of patients with breast cancer. In evaluating the results of HDC-ABMT in patients with breast cancer, an assessment of quality of life can add to the traditional endpoints (toxicity, and disease-free and overall survival) that are routinely assessed in clinical trials.


OBJECTIVE
This study evaluated the quality of life (QOL) of breast cancer patients who had survived 1 or more years following high dose chemotherapy with autologous bone marrow transplant (HDC-ABMT) support.


METHODS
Eighty-two patients who had undergone HDC-ABMT were surveyed by written questionnaire and follow-up telephone interview at least 1 year following HDC-ABMT. Patients were asked to complete the Functional Living Index-Cancer (FLIC), the Symptom Distress Scale (SDS), and a survey of sexual function developed as part of the study.


RESULTS
The mean FLIC score among all patients was 130 +/- 19.1 (possible range 22-154). FLIC scores were significantly lower in patients with evidence of recurrent disease than in patients who were free of disease. The most commonly reported symptoms after HDC-ABMT were insomnia, fatigue, and pain. Sexual interest and sexual activity were reported to be lower after participation in HDC-ABMT than prior to the procedure. The majority of patients who were employed outside the home prior to HDC-ABMT returned to work with a median time away from work of 48 weeks.


CONCLUSIONS
Patients with breast cancer who survive 1 or more years following HDC-ABMT rate their QOL at a relatively high level and frequently return to work. Less than one-third of patients who were interviewed reported moderate to severe symptoms. Problems with sexual functioning were common.


CONCLUSIONS
Future research is needed on long-term outcomes after HDC-ABMT and on specific areas of concern, such as sexual functioning.
Winer
E P
EP
Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Lindley
C
C
Hardee
M
M
Sawyer
W T
WT
Brunatti
C
C
Borstelmann
N A
NA
Peters
W
W
D000328:Adult; D016026:Bone Marrow Transplantation / Q000523:psychology*; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000175:diagnosis / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004358:Drug Therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011788:Quality of Life; D012725:Sexual Behavior / Q000523:psychology; D011795:Surveys and Questionnaires; D013534:Survival; D013997:Time Factors; D014182:Transplantation, Autologous